RxDoctor Payments DataLook up a doctor →

Adil Fatakia, MD

Otolaryngology · Marrero, LANPI 1477737914

Payments from drug & device makers

$23,177,880in general payments, 2019–2025

Across 1,439 payments — averaging $16,107 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$16M
  • Eli Lilly$2.5M
  • Amgen$1.2M
  • Braintree Laboratories, Inc.$487K
  • AbbVie$425K
  • GSK$404K
  • plus $2.2M from 38 others
$84,515in research payments, 2019–2025

Across 20 payments — averaging $4225.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$58K
  • Neurent Medical Limited$25K
  • Regeneron$1K
  • Aerin Medical Inc.$500

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$23,177,880 in reported general payments places this provider in the 95th percentile of 218 otolaryngology providers in Louisiana.

See all otolaryngology providers in Louisiana

Medicare billing

Part B allowed, 2024
$77,769
Medicare patients
165
Services billed
2,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other otolaryngology in Marrero

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →